GlassScriptPhysician profile
Michel Badin
NPI 1750305389
$3,611.12
in general payments reported to CMS, 2019-2025
42 companies · $52.45 in 2025
The $52.45 reported for 2025 was less than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $874 · 2020: $831 · 2021: $982 · 2022: $661 · 2023: $176 · 2024: $34.28 · 2025: $52.45.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $263.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $666.76 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $437.81 | 2019-2023 | Opdivo |
| Merck Sharp & Dohme LLC | $386.45 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $258.76 | 2019-2022 | |
| Amgen INC. | $238.50 | 2019-2022 | |
| Janssen Biotech, INC. | $181.66 | 2019-2024 | Darzalex, Imbruvica |
| Incyte Corporation | $130.86 | 2019-2022 | |
| Celgene Corporation | $119.39 | 2019-2021 | |
| Pfizer INC. | $117.29 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $98.99 | 2019-2025 | |
| Novo Nordisk INC | $93.10 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $63.18 | 2020-2021 | |
| Glaxosmithkline, LLC. | $57.16 | 2020-2023 | Trelegy Ellipta |
| Astellas Pharma US INC | $57.11 | 2020-2021 | |
| Eisai INC. | $55.84 | 2021-2023 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michel Badin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.